Attached files
SEGMENT INFORMATION
TECHNE CORPORATION AND SUBISIDARIES
(in thousands of $'s, except per share data)
Increase (Decrease)
Fiscal 2012 From Fiscal 2011
------------------------------- ----------------------
First Second YTD Percent First Second YTD
------ ------ ------- ------- ------ ------ ------
Sales 77,596 74,662 152,258 100% 9,651 6,954 16,605
Cost of sales 19,209 19,492 38,701 25% 3,859 4,165 8,024
------ ------ ------- ------- ------ ------ ------
Gross margin 58,387 55,170 113,557 75% 5,792 2,789 8,581
Gross margin
percentage 75.2% 73.9% 74.6%
SG&A expense 10,773 10,651 21,424 14% 3,160 2,224 5,384
R&D expense 6,667 6,837 13,504 9% 48 234 282
Interest income (728) (798) (1,526) (1%) 119 222 341
Other non-operating
ex., net 1,175 607 1,782 1% 918 (91) 827
------ ------ ------- ------- ------ ------ ------
17,887 17,297 35,184 23% 4,245 2,589 6,834
------ ------ ------- ------- ------ ------ ------
Earnings before
income taxes 40,500 37,873 78,373 52% 1,547 200 1,747
Income taxes 12,979 12,060 25,039 17% 399 921 1,320
------ ------ ------- ------- ------ ------ ------
27,521 25,813 53,334 35% 1,148 (721) 427
====== ====== ======= ======= ====== ====== ======
Diluted earnings
per share 0.74 0.70 1.44
Weighted average
diluted shares
outstanding 37,170 37,028 37,099
BIOTECHNOLOGY (1)
(in thousands of $'s)
Increase (Decrease)
Fiscal 2012 From Fiscal 2011
------------------------------- ----------------------
First Second YTD Percent First Second YTD
------ ------ ------- ------- ------ ------ ------
Sales 72,303 69,808 142,111 100% 9,262 6,728 15,990
Cost of sales 16,465 16,887 33,352 23% 3,624 4,267 7,891
------ ------ ------- ------- ------ ------ ------
Gross margin 55,838 52,921 108,759 77% 5,638 2,461 8,099
Gross margin
percentage 77.2% 75.8% 76.5%
SG&A expense 9,470 9,003 18,473 13% 2,984 2,144 5,128
R&D expense 6,469 6,624 13,093 9% 48 245 293
Interest income (609) (689) (1,298) (1%) 53 129 182
Exchange loss/gain 524 105 629 1% 1,029 18 1,047
------ ------ ------- ------- ------ ------ ------
15,854 15,043 30,897 22% 4,114 2,536 6,650
------ ------ ------- ------- ------ ------ ------
Pretax result 39,984 37,878 77,862 55% 1,524 (75) 1,449
====== ====== ======= ======= ====== ====== ======
(1) Includes R&D Systems' Biotechnology Division, R&D Systems Europe,
BiosPacific, R&D China, Boston Biochem and Tocris.
HEMATOLOGY
(in thousands of $'s)
Increase (Decrease)
Fiscal 2012 From Fiscal 2011
------------------------------- ----------------------
First Second YTD Percent First Second YTD
------ ------ ------- ------- ------ ------ ------
Sales 5,293 4,854 10,147 100% 389 226 615
Cost of sales 2,744 2,605 5,349 53% 235 (102) 133
------ ------ ------- ------- ------ ------ ------
Gross margin 2,549 2,249 4,798 47% 154 328 482
Gross margin
percentage 48.2% 46.3% 47.3%
SG&A expense 480 400 880 9% 152 64 216
R&D expense 198 213 411 4% -- (11) (11)
Interest income (47) (45) (92) (1%) 6 21 27
------ ------ ------- ------- ------ ------ ------
631 568 1,199 12% 158 74 232
------ ------ ------- ------- ------ ------ ------
Pretax result 1,918 1,681 3,599 35% (4) 254 250
====== ====== ======= ======= ====== ====== ======
CORPORATE AND OTHER (2)
(in thousands of $'s)
Increase (Decrease)
Fiscal 2012 From Fiscal 2011
----------------------- ----------------------
First Second YTD First Second YTD
------ ------ ------- ------ ------ ------
Interest income 72 64 136 (60) (72) (132)
Rental income 134 198 332 11 60 71
------ ------ ------- ------ ------ ------
206 262 468 (49) (12) (61)
SG&A expense 823 1,248 2,071 24 16 40
Other-Building expenses 587 482 1,069 31 (49) (18)
Other-Equity
Investment losses 198 218 416 (131) 0 (131)
------ ------ ------- ------ ------ ------
1,608 1,948 3,556 (76) (33) (109)
------ ------ ------- ------ ------ ------
Pretax result (1,402) (1,686) (3,088) 27 21 48
====== ====== ======= ====== ====== ======
(2) Unallocated corporate expenses and Techne's share of losses by
Hemerus Medical, LLC and Nephromics, LLC
